Skip to main content
construction release_alert
Profile editing will be unavailable for Scholars@Duke profiles from June 11-24, 2026 as manual profile data entry transitions to Elements. More information about the transition.
cancel

Emmanuel Benjamin Walter Jr.

Professor of Pediatrics
Pediatrics, General Pediatrics and Adolescent Health
27 Alexandria Way, Suite 100, RTP Box 106008, Durham, NC 27713
27 Alexandria Way, Suite 100, RTP Box 106008, Durham, NC 27713

Overview


Dr. Emmanuel Walter, MD, MPH, Professor of Pediatrics, serves as the Duke Human Vaccine Institute (DHVI) Chief Medical Officer and directs the Duke Vaccine and Trials Unit. In these roles, Dr. Walter provides strategic and operational leadership for clinical research conducted at the Institute.  In addition, he provides oversight of regulatory compliance for DHVI clinical research activities.

Dr. Walter has dedicated his career to advancing research and clinical practice in vaccinology, infectious diseases, and child health. He currently serves as the principal investigator for the Duke Clinical Core of the Collaborative Influenza Vaccine Innovations Centers (CIVICs) funded by the National Institute of Allergy and Infectious Diseases (NIAID).  The goal of this work is to evaluate promising next generation influenza vaccine candidates in Phase I and Phase I/II clinical trials and human challenge studies.  He is also the Duke Principal Investigator for the CDC-funded Clinical Immunization Safety Assessment Project which conducts studies to identify risk factors and preventive strategies for adverse events following immunization, particularly in special populations. Lastly, he is the Principal Investigator for the  CDC-funded coordinating center of the influenza and other respiratory virus vaccine effectiveness network.  This work provides national estimates for influenza and other respiratory virus vaccine effectiveness in persons presenting with respiratory illness in the ambulatory setting.

Dr. Walter's focused area of interest include vaccine development, vaccine safety, vaccine effectiveness, vaccine coverage, prevention and treatment of infectious diseases.

Current Appointments & Affiliations


Professor of Pediatrics · 2009 - Present Pediatrics, General Pediatrics and Adolescent Health, Pediatrics
Member of the Duke Human Vaccine Institute · 2013 - Present Duke Human Vaccine Institute, Institutes and Centers
Affiliate, Duke Global Health Institute · 2020 - Present Duke Global Health Institute, University Institutes and Centers

In the News


Published May 18, 2023
Duke Health Leads Its First Clinical Trial Testing a New Universal Flu Vaccine
Published March 30, 2021
Duke Enrolls First-in-Nation Children for Pfizer-BioNTech U.S. Clinical Study Trial in Children Under 12
Published November 6, 2020
Years in the Making: Duke Human Vaccine Institute Researchers Attack COVID-19

View All News

Recent Publications


Preventing Postvaccination Presyncope and Syncope in Adolescents: A Randomized Controlled Trial of a Clinic-Based Intervention.

Journal Article J Pediatr · June 2026 OBJECTIVE: To study the impact of a combined intervention using Buzzy plus simultaneous distraction (playing video games on a tablet) on the incidence of postvaccination presyncope and syncope. STUDY DESIGN: We performed a randomized-controlled trial of a ... Full text Link to item Cite

Influenza vaccine effectiveness against outpatient acute respiratory illness with laboratory-confirmed influenza, United States, 2024-25 season.

Journal Article medRxiv · March 26, 2026 BACKGROUND: Influenza A(H1N1)pdm09 and A(H3N2) viruses predominated during the 2024-25 U.S. influenza season. We estimated influenza vaccine effectiveness (VE) in the United States against mild-to-moderate outpatient influenza illness by influenza type and ... Full text Link to item Cite

The neutralizing antibody titer correlate of COVID-19 risk in the COVID-19 variant immunologic landscape (COVAIL) trial was not modified by SARS-CoV-2 amino acid sequence distances.

Journal Article Vaccine · March 19, 2026 In the Coronavirus Variant Immunologic Landscape Trial (COVAIL) conducted in the United States in 2022-2023, 985 participants received a second COVID-19 booster with one of twelve monovalent or bivalent mRNA inserts. Pseudovirus serum inhibitory dilution 5 ... Full text Link to item Cite
View All Publications

Recent Grants


CIVICS Component C - Option 13B.1 Biorepository

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2026 - 2030

Duke University Maternal-Fetal Medicine Units (MFMU) Network Clinical Center

ResearchCollaborating Investigator · Awarded by Eunice Kennedy Shriver National Institute of Child Health and Human Development · 2023 - 2030

CIVICS Component C - Option 16 EA - COBRA

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2019 - 2029

View All Grants

Education


University of North Carolina, Chapel Hill · 1992 M.P.H.
University of Maryland, Baltimore · 1983 M.D.
University of Notre Dame · 1979 B.S.